Pieris Historical Balance Sheet

PIRS Stock

USD 16.83 0.24 1.41%

Trend analysis of Pieris Pharmaceuticals balance sheet accounts such as Total Stockholder Equity of 28.8 M, Property Plant And Equipment Net of 25 M, Accounts Payable of 3.6 M or Cash of 16.5 M provides information on Pieris Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Pieris Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Pieris Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Pieris Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Pieris Pharmaceuticals is a good buy for the upcoming year.

Pieris Pharmaceuticals Inventory

4.94 Million

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pieris Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Pieris Stock please use our How to Invest in Pieris Pharmaceuticals guide.

About Pieris Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Pieris Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Pieris Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Pieris Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Pieris currently owns. An asset can also be divided into two categories, current and non-current.

Pieris Pharmaceuticals Balance Sheet Chart

At this time, Pieris Pharmaceuticals' Other Liabilities is comparatively stable compared to the past year. Short Term Investments is likely to gain to about 15.9 M in 2024, whereas Short and Long Term Debt Total is likely to drop slightly above 10.4 M in 2024.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities Common Stock Total Equity Common Stock

Add Fundamental

Total Assets

Total assets refers to the total amount of Pieris Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Pieris Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Pieris Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Pieris Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Common Stock Total Equity

The total value of common stock equity held by shareholders, representing their ownership interest in the company.

Most accounts from Pieris Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Pieris Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pieris Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Pieris Stock please use our How to Invest in Pieris Pharmaceuticals guide.At this time, Pieris Pharmaceuticals' Other Liabilities is comparatively stable compared to the past year. Short Term Investments is likely to gain to about 15.9 M in 2024, whereas Short and Long Term Debt Total is likely to drop slightly above 10.4 M in 2024.

	2021	2022	2023	2024 (projected)
Short and Long Term Debt Total	13.8M	13.1M	15.1M	10.4M
Total Assets	153.6M	95.5M	38.7M	36.7M

Short Long Term Debt Total Total Assets

Pieris Pharmaceuticals balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Other Liab
Total Assets		0.7	0.4	0.9	0.8	0.52	-0.89	-0.49	0.77	0.92	0.68	0.74	0.49	0.98	0.55	0.7	0.55	0.91	0.18	0.45	0.66	0.97	0.97	0.06	0.33	0.9
Short Long Term Debt Total	0.7		0.04	0.53	0.76	0.49	-0.63	-0.56	0.5	0.63	0.59	0.77	0.5	0.68	0.39	0.86	0.73	0.7	0.2	0.5	0.68	0.59	0.71	0.55	0.31	0.67
Other Current Liab	0.4	0.04		0.5	0.32	0.48	-0.48	-0.52	0.44	0.49	0.44	0.14	0.36	0.38	-0.1	0.41	0.22	0.35	0.57	0.59	0.54	0.38	0.39	-0.48	0.74	0.28
Total Current Liabilities	0.9	0.53	0.5		0.54	0.35	-0.8	-0.43	0.6	0.79	0.53	0.47	0.28	0.89	0.67	0.6	0.44	0.8	0.25	0.39	0.56	0.95	0.88	0.04	0.38	0.84
Total Stockholder Equity	0.8	0.76	0.32	0.54		0.64	-0.8	-0.62	0.82	0.82	0.64	0.85	0.56	0.81	0.13	0.78	0.68	0.73	0.33	0.65	0.74	0.63	0.83	0.16	0.39	0.67
Property Plant And Equipment Net	0.52	0.49	0.48	0.35	0.64		-0.41	-0.91	0.65	0.49	0.92	0.78	0.91	0.43	0.08	0.74	0.72	0.71	0.72	0.86	0.87	0.42	0.54	-0.24	0.66	0.55
Net Debt	-0.89	-0.63	-0.48	-0.8	-0.8	-0.41		0.4	-0.66	-0.98	-0.52	-0.66	-0.4	-0.92	-0.28	-0.62	-0.46	-0.74	-0.17	-0.49	-0.56	-0.83	-0.88	-0.13	-0.29	-0.74
Retained Earnings	-0.49	-0.56	-0.52	-0.43	-0.62	-0.91	0.4		-0.56	-0.43	-0.82	-0.7	-0.76	-0.42	-0.11	-0.85	-0.86	-0.65	-0.88	-0.95	-0.94	-0.39	-0.55	0.09	-0.76	-0.54
Accounts Payable	0.77	0.5	0.44	0.6	0.82	0.65	-0.66	-0.56		0.71	0.69	0.69	0.43	0.74	0.34	0.64	0.52	0.74	0.41	0.56	0.67	0.67	0.77	-0.07	0.44	0.66
Cash	0.92	0.63	0.49	0.79	0.82	0.49	-0.98	-0.43	0.71		0.62	0.73	0.5	0.92	0.29	0.64	0.48	0.77	0.18	0.51	0.61	0.85	0.87	0.06	0.3	0.74
Non Current Assets Total	0.68	0.59	0.44	0.53	0.64	0.92	-0.52	-0.82	0.69	0.62		0.81	0.87	0.58	0.34	0.81	0.74	0.82	0.56	0.74	0.88	0.63	0.63	-0.13	0.66	0.67
Non Currrent Assets Other	0.74	0.77	0.14	0.47	0.85	0.78	-0.66	-0.7	0.69	0.73	0.81		0.76	0.69	0.21	0.8	0.83	0.8	0.39	0.68	0.8	0.62	0.73	0.11	0.29	0.68
Other Assets	0.49	0.5	0.36	0.28	0.56	0.91	-0.4	-0.76	0.43	0.5	0.87	0.76		0.41	0.01	0.64	0.61	0.67	0.46	0.71	0.74	0.42	0.47	-0.21	0.52	0.52
Cash And Short Term Investments	0.98	0.68	0.38	0.89	0.81	0.43	-0.92	-0.42	0.74	0.92	0.58	0.69	0.41		0.48	0.66	0.5	0.88	0.12	0.4	0.59	0.95	0.97	0.07	0.29	0.89
Net Receivables	0.55	0.39	-0.1	0.67	0.13	0.08	-0.28	-0.11	0.34	0.29	0.34	0.21	0.01	0.48		0.3	0.18	0.54	-0.04	-0.05	0.19	0.66	0.51	0.35	0.06	0.61
Common Stock Total Equity	0.7	0.86	0.41	0.6	0.78	0.74	-0.62	-0.85	0.64	0.64	0.81	0.8	0.64	0.66	0.3		0.91	0.75	0.6	0.8	0.95	0.6	0.71	0.21	0.68	0.66
Common Stock Shares Outstanding	0.55	0.73	0.22	0.44	0.68	0.72	-0.46	-0.86	0.52	0.48	0.74	0.83	0.61	0.5	0.18	0.91		0.66	0.68	0.79	0.91	0.43	0.58	0.12	0.53	0.55
Non Current Liabilities Total	0.91	0.7	0.35	0.8	0.73	0.71	-0.74	-0.65	0.74	0.77	0.82	0.8	0.67	0.88	0.54	0.75	0.66		0.33	0.58	0.74	0.89	0.92	-0.05	0.45	0.97
Inventory	0.18	0.2	0.57	0.25	0.33	0.72	-0.17	-0.88	0.41	0.18	0.56	0.39	0.46	0.12	-0.04	0.6	0.68	0.33		0.89	0.74	0.1	0.28	-0.21	0.7	0.23
Other Current Assets	0.45	0.5	0.59	0.39	0.65	0.86	-0.49	-0.95	0.56	0.51	0.74	0.68	0.71	0.4	-0.05	0.8	0.79	0.58	0.89		0.88	0.33	0.53	-0.09	0.72	0.47
Other Stockholder Equity	0.66	0.68	0.54	0.56	0.74	0.87	-0.56	-0.94	0.67	0.61	0.88	0.8	0.74	0.59	0.19	0.95	0.91	0.74	0.74	0.88		0.55	0.66	-0.04	0.77	0.61
Total Liab	0.97	0.59	0.38	0.95	0.63	0.42	-0.83	-0.39	0.67	0.85	0.63	0.62	0.42	0.95	0.66	0.6	0.43	0.89	0.1	0.33	0.55		0.92	0.01	0.27	0.9
Total Current Assets	0.97	0.71	0.39	0.88	0.83	0.54	-0.88	-0.55	0.77	0.87	0.63	0.73	0.47	0.97	0.51	0.71	0.58	0.92	0.28	0.53	0.66	0.92		0.08	0.35	0.94
Short Term Debt	0.06	0.55	-0.48	0.04	0.16	-0.24	-0.13	0.09	-0.07	0.06	-0.13	0.11	-0.21	0.07	0.35	0.21	0.12	-0.05	-0.21	-0.09	-0.04	0.01	0.08		-0.2	0.03
Common Stock	0.33	0.31	0.74	0.38	0.39	0.66	-0.29	-0.76	0.44	0.3	0.66	0.29	0.52	0.29	0.06	0.68	0.53	0.45	0.7	0.72	0.77	0.27	0.35	-0.2		0.36
Other Liab	0.9	0.67	0.28	0.84	0.67	0.55	-0.74	-0.54	0.66	0.74	0.67	0.68	0.52	0.89	0.61	0.66	0.55	0.97	0.23	0.47	0.61	0.9	0.94	0.03	0.36

Click cells to compare fundamentals

Pieris Pharmaceuticals Account Relationship Matchups

Pieris Pharmaceuticals balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	141.1M	105.0M	153.6M	95.5M	38.7M	36.7M
Other Current Liab	5.0M	6.6M	15.8M	10.7M	8.6M	6.6M
Total Current Liabilities	27.0M	22.1M	50.6M	36.6M	11.9M	11.3M
Total Stockholder Equity	51.4M	31.0M	50.8M	27.9M	26.8M	28.8M
Property Plant And Equipment Net	22.9M	26.0M	23.0M	20.7M	23.8M	25.0M
Net Debt	(46.0M)	(53.5M)	(103.9M)	(25.5M)	(17.4M)	(18.3M)
Retained Earnings	(174.2M)	(211.4M)	(257.1M)	(290.4M)	(315.0M)	(299.2M)
Accounts Payable	10.1M	1.8M	8.6M	4.2M	3.4M	3.6M
Cash	62.3M	70.4M	117.8M	38.6M	17.4M	16.5M
Non Current Assets Total	26.1M	29.3M	25.9M	22.1M	25.4M	13.5M
Non Currrent Assets Other	3.1M	3.3M	2.9M	1.4M	1.6M	1.1M
Other Assets	910K	3.1M	7.2M	2.9M	3.3M	3.5M
Cash And Short Term Investments	104.2M	70.4M	117.8M	59.2M	26.4M	25.0M
Net Receivables	6.8M	1.7M	3.3M	5.8M	572K	543.4K
Common Stock Total Equity	54K	55K	56K	72K	82.8K	42.7K
Common Stock Shares Outstanding	632.8K	681.0K	806.8K	927.2K	1.1M	674.0K
Liabilities And Stockholders Equity	141.1M	105.0M	153.6M	95.5M	38.7M	36.7M
Non Current Liabilities Total	62.7M	51.8M	52.2M	31.0M	35.6M	30.4M
Other Current Assets	4.1M	7.2M	13.1M	8.4M	11.7M	12.3M
Other Stockholder Equity	227.5M	242.7M	307.0M	318.5M	341.6M	201.9M
Total Liab	89.7M	74.0M	102.8M	67.6M	11.9M	11.3M
Total Current Assets	115.0M	75.7M	127.6M	73.4M	38.7M	69.0M
Common Stock	55K	56K	72K	74K	98K	57.9K
Other Liab	47.3M	35.9M	38.4M	18.7M	21.5M	26.7M
Net Tangible Assets	51.4M	31.0M	50.8M	27.9M	32.1M	31.6M
Current Deferred Revenue	11.3M	12.6M	25.1M	20.8M	23.9M	17.9M
Retained Earnings Total Equity	(147.1M)	(174.2M)	(211.4M)	(257.1M)	(231.4M)	(219.9M)
Short Term Investments	34.8M	53.2M	41.9M	20.5M	9.0M	15.9M
Capital Surpluse	189.9M	227.5M	242.7M	307.0M	353.0M	370.7M
Property Plant And Equipment Gross	22.9M	22.0M	23.0M	20.7M	23.8M	25.0M
Accumulated Other Comprehensive Income	(2.0M)	(295K)	829K	(254K)	28K	29.4K
Non Current Liabilities Other	27K	62.7M	6K	52.2M	60.1M	63.1M
Property Plant Equipment	19.5M	26.0M	23.0M	20.7M	23.8M	25.0M
Net Invested Capital	51.4M	31.0M	50.8M	27.9M	32.1M	39.0M
Net Working Capital	88.0M	53.6M	77.1M	36.8M	33.2M	51.6M
Capital Stock	55K	56K	72K	74K	85.1K	68.4K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Pieris Stock Analysis

When running Pieris Pharmaceuticals' price analysis, check to measure Pieris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pieris Pharmaceuticals is operating at the current time. Most of Pieris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Pieris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pieris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Pieris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Pieris Historical Balance Sheet

Pieris Pharmaceuticals Inventory

4.94 Million

About Pieris Balance Sheet Analysis

Pieris Pharmaceuticals Balance Sheet Chart

Total Assets

Total Current Liabilities

Common Stock Total Equity

Pieris Pharmaceuticals balance sheet Correlations

Pieris Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Pieris Pharmaceuticals balance sheet Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Pieris Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 0.98	Total Assets
Total Liab	+ 0.97	Total Assets
Total Current Assets	+ 0.97	Total Assets
Total Current Assets	+ 0.97	Cash And Short Term Investments
Other Liab	+ 0.97	Non Current Liabilities Total
Total Liab	+ 0.95	Total Current Liabilities

Cash	- 0.98	Net Debt
Other Current Assets	- 0.95	Retained Earnings
Other Stockholder Equity	- 0.94	Retained Earnings
Cash And Short Term Investments	- 0.92	Net Debt
Retained Earnings	- 0.91	Property Plant And Equipment Net
Net Debt	- 0.89	Total Assets